Filtered By:
Drug: Fortamet

This page shows you your search results in order of relevance. This is page number 19.

Order by Relevance | Date

Total 9822 results found since Jan 2013.

Trends in prescribing anti ‐obesity pharmacotherapy for paediatric weight management: Data from the POWER Work Group
ConclusionsThese data suggest the need for (a) additional robust paediatric drug trials to further develop the evidence base guiding use or non ‐use of pharmacotherapy in paediatric weight management, and (b) increased understanding of both facilitators and barriers to prescribing anti‐obesity pharmacotherapy for youth with obesity.
Source: Pediatric Obesity - September 1, 2020 Category: Eating Disorders & Weight Management Authors: Claudia Borzutzky, Eileen King, Claudia K Fox, William Stratbucker, Jared Tucker, Jennifer K Yee, Seema Kumar, Suzanne Cuda, Brooke Sweeney, Shelley Kirk, on behalf of the POWER Work Group Tags: ORIGINAL RESEARCH Source Type: research

A Randomized Encouragement Trial to Increase Mail Order Pharmacy Use and Medication Adherence in Patients with Diabetes
ConclusionThis pragmatic trial showed that simple outreach to encourage MOP modestly increased its use and improved adherence measured by refills to a key class of diabetes medications in some settings. Given its minimal cost, clinicians and health systems should consider outreach interventions to actively promote MOP use among diabetes patients.Trial RegistrationClinicalTrials.gov registration number: NCT02621476
Source: Journal of General Internal Medicine - September 30, 2020 Category: Internal Medicine Source Type: research

lncRNA MALAT1 participates in metformin inhibiting the proliferation of breast cancer cell
J Cell Mol Med. 2021 Jun 24. doi: 10.1111/jcmm.16742. Online ahead of print.ABSTRACTIn recent years, the repurposing of conventional and chemotherapeutic drugs is recognized as an alternative strategy for health care. The main purpose of this study is to strengthen the application of non-oncological drug metformin on breast cancer treatment in the perspective of epigenetics. In the present study, metformin was found to inhibit cell proliferation, promote apoptosis and induce cell cycle arrest in breast cancer cells at a dose-dependent manner. In addition, metformin treatment elevated acH3K9 abundance and decreased acH3K18 ...
Source: Molecular Medicine - June 24, 2021 Category: Molecular Biology Authors: Yongye Huang Ziyan Zhou Jin Zhang Zhenzhen Hao Yunhao He Zihan Wu Yiquan Song Kexun Yuan Shanyu Zheng Qi Zhao Tianye Li Bing Wang Source Type: research

First-Line Therapy for Type 2 Diabetes With Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists : A Cost-Effectiveness Study
CONCLUSION: As first-line agents, SGLT2 inhibitors and GLP1 receptor agonists would improve type 2 diabetes outcomes, but their costs would need to fall by at least 70% to be cost-effective.PRIMARY FUNDING SOURCE: American Diabetes Association.PMID:36191315 | DOI:10.7326/M21-2941
Source: Annals of Internal Medicine - October 3, 2022 Category: Internal Medicine Authors: Jin G Choi Aaron N Winn M Reza Skandari Melissa I Franco Erin M Staab Jason Alexander Wen Wan Mengqi Zhu Elbert S Huang Louis Philipson Neda Laiteerapong Source Type: research

Add-on imeglimin versus metformin dose escalation regarding glycemic control in patients with type 2 diabetes treated with a dipeptidyl peptidase-4 inhibitor plus low-dose metformin: study protocol for a multicenter, prospective, randomized, open-label, parallel-group comparison study (MEGMI study)
CONCLUSIONS: This will be the first randomized controlled trial to compare the efficacy of adding imeglimin versus metformin dose escalation on glycemic control in patients with T2D.TRIAL REGISTRATION NUMBER: jRCT1011220005.PMID:36379585 | DOI:10.1136/bmjdrc-2022-002988
Source: Molecular Medicine - November 15, 2022 Category: Molecular Biology Authors: Hiroshi Nomoto Akihiro Takahashi Akinobu Nakamura Hiroyoshi Kurihara Jun Takeuchi So Nagai Shinji Taneda Aika Miya Hiraku Kameda Kyu Yong Cho Hideaki Miyoshi Tatsuya Atsumi Source Type: research

Metformin therapy in pediatric type 2 diabetes mellitus and its comorbidities: A review
Type 2 diabetes (T2D) rates in children and adolescents are rising globally. T2D is a complex and aggressive disease in children with several comorbidities, high treatment failure rates, and insulin needs within a few years from diagnosis. While myriads of pharmacotherapies are licensed to treat adults with T2D, treatments accessible to children and adolescents have been limited until recently. Metformin is an old drug with multiple beneficial metabolic health effects beyond glycemic control. This review discusses Metformin’s origins, its mechanisms of action, and evidence for its use in the pediatric population to treat...
Source: Frontiers in Endocrinology - February 6, 2023 Category: Endocrinology Source Type: research

Primary Occurrence of Cardiovascular Events After Adding Sodium-Glucose Cotransporter-2 Inhibitors or Glucagon-like Peptide-1 Receptor Agonists Compared With Dipeptidyl Peptidase-4 Inhibitors: A Cohort Study in Veterans With Diabetes
CONCLUSION: The addition of GLP1RA was associated with primary reductions of MACE and HF hospitalization compared with DPP4i use; SGLT2i addition was not associated with primary MACE prevention.PRIMARY FUNDING SOURCE: VA Clinical Science Research and Development and supported in part by the Centers for Diabetes Translation Research.PMID:37155984 | DOI:10.7326/M22-2751
Source: Annals of Internal Medicine - May 8, 2023 Category: Internal Medicine Authors: Tadarro L Richardson Alese E Halvorson Amber J Hackstadt Adriana M Hung Robert Greevy Carlos G Grijalva Tom A Elasy Christianne L Roumie Source Type: research